Doxazosin Treatment in Patients with Prostatic Obstruction

Abstract

The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. By patients' overall assessment of voiding difficulties, 79% in the doxazosin group (DG) and 44% in the placebo group (PG) reported improvement (p = 0.001). In the DG, improvement was noted in 63% of obstructive symptoms compared to 32% in the PG (p = 0.015), whereas improvement was noted in 76% and 45%, respectively, of irritative symptoms (p = 0.12). Daytime frequency was reduced by 1.5 in the DG and increased by 0.3 in the PG (p = 0.001), and nocturia was reduced by 1.1 and 1.0, respectively (p = 0.12). Maximum urinary flow rate was improved by 1.5 ml/s in the DG, while it deteriorated by 0.3 ml/s in the PG (p = 0.11). Considering postvoid residual urine volume, cystometry variables (first sensation and bladder capacity) and adverse events there was no difference between the two groups. In conclusion, doxazosin 4 mg once daily is safe and effective in relieving symptoms in patients with BPH.

Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature

“…Significant improvements in the signs and symptoms of BPH have been reported in a number of clinical trials of doxazosin [59, 60, 61, 62, 63, 64, 65, 66, 67](table 1, 2, 3), and improvement has been shown to correlate with plasma drug concentration [68]. …”

Tolerability of -Blockade With Doxazosin as a Therapeutic Option for Symptomatic Benign Prostatic Hyperplasia in the Elderly Patient: A Pooled Analysis of Seven Double-Blind, Placebo-Controlled Studies

“…Results from two of the trials reported by Janknegt et al (19) have since been published independently (22)(23)(24), and results have been supplemented with data on file.…”

Double–Blind Trial of the Efficacy and Tolerability of Doxazosin in the Gastrointestinal Therapeutic System, Doxazosin Standard, and Placebo in Patients with Benign Prostatic Hyperplasia

“…In numerous clinical trials, doxazosin mesylate has produced significant symptomatic relief and marked increases in maximum and mean urinary flow rates among older and younger men with BPH, usually at final titrated doses of 4 mg to 8 mg once daily [3, 4, 5, 6, 7, 8, 9, 10, 11]. Doxazosin mesylate in its standard formulation requires careful titration from an initial dose of 1 mg once daily (usually a clinically ineffective dose), gradually doubled until optimal symptomatic relief and improvements in urinary flow are achieved.…”